Biosynthesis of SeNPs by Mycobacterium bovis and their enhancing effect on the immune response against HBs antigens: an in vivo study

Biosynthesis of SeNPs by Mycobacterium bovis and their enhancing effect on the immune response against HBs antigens: an in vivo study

For access to this article, please select a purchase option:

Buy article PDF
(plus tax if applicable)
Buy Knowledge Pack
10 articles for £75.00
(plus taxes if applicable)

IET members benefit from discounts to all IET publications and free access to E&T Magazine. If you are an IET member, log in to your account and the discounts will automatically be applied.

Learn more about IET membership 

Recommend Title Publication to library

You must fill out fields marked with: *

Librarian details
Your details
Why are you recommending this title?
Select reason:
IET Nanobiotechnology — Recommend this title to your library

Thank you

Your recommendation has been sent to your librarian.

Conventional hepatitis B vaccine contains alum but is less effective to induce Th1 response. Selenium nanoparticles and Bacillus Calmette–Guerin were reported as immune modulators. In this study, SeNPs were extracted from Mycobacterium bovis and characterised. SeNPs were mixed with HBs-Ag and administered to the mice to investigate he immune response pattern. With an addition of Se ions at a sub-inhibitory concentration to the Sauton medium broth after 24 h, SeNPs were extracted from M. bovis and characterised by Fourier transform infrared spectroscopy, dynamic light scattering, atomic forcemicroscopy, energy dispersive X-ray spectrum, transmission electron microscopy, and thermogravimetric analysis. Furthermore, female inbred BALB/c mice were injected subcutaneously on the first, 14th, 28th day with 100 and 200 µg doses of that SeNPs supplemented with HBs-Ag vaccine. Later, the total antibody, isotypes of Immunoglobulin G1, Interlukin 4, and interferon-γ were measured by enzye-linked immunosorbent assay. The size of the SeNPs was <150 nm. Level of total antibody and immunoglobulin G2a increased significantly in the group that received 200 µg/ml nano selenium extracted from M. bovis. SeNPs in dose of 200 µg coated with organic materials of M. bovis could induce an influential immune response in relation to the conventional HBs-Ag vaccine.


    1. 1)
      • 1. Alavian, S.M.: ‘Networking for overcoming on viral hepatitis in Middle East and Central Asia: Asian hepatitis network’, Hepat. Mon., 2007, 7, (4), pp. 181182.
    2. 2)
      • 2. Bhattacharya, D., Thio, C.L.: ‘Review of hepatitis B therapeutics’, Clin. Infect. Dis., 2010, 51, (10), pp. 12011208.
    3. 3)
      • 3. Aspinall, E., Hawkins, G., Fraser, A., et al: ‘Hepatitis B prevention, diagnosis, treatment and care: a review’, Occup. Med., 2011, 61, (8), pp. 531540.
    4. 4)
      • 4. Koumbi, L., Karayiannis, P.: ‘The epigenetic control of hepatitis B virus modulates the outcome of infection’, Front. Microbiol., 2016, 6, pp. 1491.
    5. 5)
      • 5. Koike, Y., Yoo, Y.C., Mitobe, M., et al: ‘Enhancing activity of mycobacterial cell-derived adjuvants on immunogenicity of recombinant human hepatitis B virus vaccine’, Vaccine, 1998, 16, (20), pp. 19821989.
    6. 6)
      • 6. Cardell, K.: ‘Studies on hepatitis B vaccination and factors associated with the vaccine response’, 2009.
    7. 7)
      • 7. Oleszycka, E., Lavelle, E.C.: ‘Immunomodulatory properties of the vaccine adjuvant alum’, Curr. Opin. Immunol., 2014, 28, pp. 15.
    8. 8)
      • 8. Taniyama, T., Watanabe, T., Azuma, I., et al: ‘Adjuvant activity of mycobacterial fractions’, Jpn. J. Microbiol., 1974, 18, (6), pp. 415426.
    9. 9)
      • 9. Mohan, T., Verma, P., Rao, D.N.: ‘Novel adjuvants & delivery vehicles for vaccines development: a road ahead’, Indian J. Med. Res., 2013, 138, (5), p. 779.
    10. 10)
      • 10. Lin, Y.C., Chang, M.-H., Ni, Y.H., et al: ‘Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan’, J. Infect. Dis., 2003, 187, (1), pp. 134138.
    11. 11)
      • 11. Whittle, H., Pilkington, J., Maine, N., et al: ‘Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages’, Lancet, 1995, 345, (8957), pp. 10891092.
    12. 12)
      • 12. Borges, O., Silva, M., de Sousa, A., et al: ‘Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen’, Int. Immunopharmacol., 2008, 8, (13), pp. 17731780.
    13. 13)
      • 13. Levast, B., Awate, S., Babiuk, L., et al: ‘Vaccine potentiation by combination adjuvants’, Vaccines, 2014, 2, (2), pp. 297322.
    14. 14)
      • 14. Stephenson, R., You, H., McManus, D.P., et al: ‘Schistosome vaccine adjuvants in preclinical and clinical research’, Vaccines, 2014, 2, (3), pp. 654685.
    15. 15)
      • 15. Kundi, M.: ‘New hepatitis B vaccine formulated with an improved adjuvant system’, Expert Rev. Vaccines, 2007, 6, (2), pp. 133140.
    16. 16)
      • 16. Yoo, Y.C., Hata, K., Lee, K.B., et al: ‘Inhibitory effect of BCG cell-wall skeletons (BCG-CWS) emulsified in squalane on tumor growth and metastasis in mice’, Arch. Pharm. Res., 2002, 25, (4), pp. 522527.
    17. 17)
      • 17. Li, Q., Normolle, D.P., Sayre, D.M., et al: ‘Immunological effects of BCG as an adjuvant in autologous tumor vaccines’, J. Clin. Immunol., 2000, 94, (1), pp. 6472.
    18. 18)
      • 18. Shirsat, S., Kadam, A., Naushad, M., et al: ‘Selenium nanostructures: microbial synthesis and applications’, RSC Adv., 2015, 5, (112), pp. 9279992811.
    19. 19)
      • 19. Yazdi, M.H., Mahdavi, M., Varastehmoradi, B., et al: ‘The immunostimulatory effect of biogenic selenium nanoparticles on the 4T1 breast cancer model: an in vivo study’, Biol. Trace Elem. Res., 2012, 149, (1), pp. 2228.
    20. 20)
      • 20. Mahdavi, M., Mavandadnejad, F., Yazdi, M.H., et al: ‘Oral administration of synthetic selenium nanoparticles induced robust Th1 cytokine pattern after HBs antigen vaccination in mouse model’, J. Infect. Public Health, 2016, doi: 10.1016/j.jiph.2016.02.006.
    21. 21)
      • 21. Lukac, N., Massányi, P.: ‘Effects of trace elements on the immune system’, Epidemiol. Microbiol. Immunol., 2007, 56, (1), pp. 39.
    22. 22)
      • 22. Yazdi, M.H., Varastehmoradi, B., Faghfuri, E., et al: ‘Adjuvant effect of biogenic selenium nanoparticles improves the immune responses and survival of mice receiving 4T1 cell antigens as vaccine in breast cancer murine model’, J. Nanosci. Nanotechnol., 2015, 15, (12), pp. 1016510172.
    23. 23)
      • 23. Dittmer, U., Peterson, K.E., Messer, R., et al: ‘Role of interleukin-4 (IL-4), IL-12, and gamma interferon in primary and vaccine-primed immune responses to friend retrovirus infection’, J. Virol., 2001, 75, (2), pp. 654660.
    24. 24)
      • 24. Snapper, C.M., Paul, W.E.: ‘Interferon-and B cell stimulatory factor-1 reciprocally regulate Ig isotype production’, Science, 1987, 236, (4804), pp. 944947.
    25. 25)
      • 25. Plotkin, S.A.: ‘Correlates of protection induced by vaccination’, Clin. Vaccine Immunol., 2010, 17, (7), pp. 10551065.
    26. 26)
      • 26. Amanna, I.J., Slifka, M.K.: ‘Contributions of humoral and cellular immunity to vaccine-induced protection in humans’, Virology, 2011, 411, (2), pp. 206215.
    27. 27)
      • 27. Lan, Q., Zheng, T., Rothman, N., et al: ‘Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma’, Blood, 2006, 107, (10), pp. 41014108.
    28. 28)
      • 28. Byars, N.E., Nakano, G., Welch, M., et al: ‘Improvement of hepatitis B vaccine by the use of a new adjuvant’, Vaccine, 1991, 9, (5), pp. 309318.
    29. 29)
      • 29. Dezfuli, H.T., Shahbazzadeh, D., Eidi, A., et al: ‘Induction of IFN-γ cytokine response against hepatitis B surface antigen using melittin’, Gastroenterol. Hepatol. Bed Bench, 2014, 7, (2), p. 108.

Related content

This is a required field
Please enter a valid email address